TR199700522A3 - Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim. - Google Patents

Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim.

Info

Publication number
TR199700522A3
TR199700522A3 TR97/00522A TR9700522A TR199700522A3 TR 199700522 A3 TR199700522 A3 TR 199700522A3 TR 97/00522 A TR97/00522 A TR 97/00522A TR 9700522 A TR9700522 A TR 9700522A TR 199700522 A3 TR199700522 A3 TR 199700522A3
Authority
TR
Turkey
Prior art keywords
pharmaceutical composition
composition containing
selective serotonin
absorption inhibitors
containing mirtazapine
Prior art date
Application number
TR97/00522A
Other languages
English (en)
Other versions
TR199700522A2 (tr
Inventor
Johannes Nickolson Victor
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199700522(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of TR199700522A2 publication Critical patent/TR199700522A2/tr
Publication of TR199700522A3 publication Critical patent/TR199700522A3/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR97/00522A 1996-06-19 1997-06-19 Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim. TR199700522A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (2)

Publication Number Publication Date
TR199700522A2 TR199700522A2 (tr) 1998-01-21
TR199700522A3 true TR199700522A3 (tr) 1998-01-21

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/00522A TR199700522A3 (tr) 1996-06-19 1997-06-19 Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim.

Country Status (25)

Country Link
US (1) US5977099A (tr)
JP (2) JP4925074B2 (tr)
KR (1) KR100481254B1 (tr)
CN (1) CN1132581C (tr)
AR (1) AR007609A1 (tr)
AT (1) ATE213159T1 (tr)
AU (1) AU727851B2 (tr)
BR (1) BR9703624A (tr)
CA (1) CA2208199C (tr)
CZ (1) CZ290691B6 (tr)
DE (1) DE69710390T2 (tr)
DK (1) DK0813873T3 (tr)
ES (1) ES2172744T3 (tr)
HK (1) HK1006081A1 (tr)
HU (1) HU225534B1 (tr)
ID (1) ID17051A (tr)
IL (1) IL121076A (tr)
NO (1) NO313177B1 (tr)
NZ (1) NZ328113A (tr)
PL (1) PL188520B1 (tr)
PT (1) PT813873E (tr)
RU (1) RU2181287C2 (tr)
SG (1) SG60073A1 (tr)
TR (1) TR199700522A3 (tr)
ZA (1) ZA975335B (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP2001522891A (ja) * 1997-11-14 2001-11-20 アクゾ・ノベル・エヌ・ベー 睡眠時無呼吸を治療するためのミルタザピンの使用
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
EP1178805A4 (en) * 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
RU2268725C2 (ru) * 2000-01-19 2006-01-27 Акцо Нобель Н.В. Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
AU2002237847A1 (en) * 2001-02-12 2002-08-28 Akzo Nobel N.V Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
MXPA04009123A (es) * 2002-03-21 2005-09-08 C Hinz Martin Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina.
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
DK1575590T3 (da) * 2002-12-27 2008-02-11 Otsuka Pharma Co Ltd Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser
CA2516653A1 (en) * 2003-02-21 2004-09-10 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
JP4343948B2 (ja) 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
ES2426915T3 (es) 2003-09-10 2013-10-25 Brentwood Equities Ltd. Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
EP1814589B1 (en) * 2004-11-19 2015-04-15 MSD Oss B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20160072276A (ko) 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010143628A1 (ja) 2009-06-09 2010-12-16 住友重機械工業株式会社 ハイブリッド式ショベル及びその制御方法
US8785453B2 (en) * 2009-11-13 2014-07-22 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
EA201492175A1 (ru) 2012-06-06 2015-10-30 Орексиджен Терапьютикс, Инк. Способы лечения избыточного веса и ожирения

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
CN1155410C (zh) * 1997-10-03 2004-06-30 卡里药品公司 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物

Also Published As

Publication number Publication date
HUP9701068A2 (hu) 1998-08-28
CN1132581C (zh) 2003-12-31
JP4925074B2 (ja) 2012-04-25
RU2181287C2 (ru) 2002-04-20
JPH1067663A (ja) 1998-03-10
SG60073A1 (en) 1999-02-22
CN1173330A (zh) 1998-02-18
DK0813873T3 (da) 2002-05-27
CZ187097A3 (cs) 1998-01-14
IL121076A (en) 2000-10-31
DE69710390T2 (de) 2002-08-14
ZA975335B (en) 1998-01-26
PL188520B1 (pl) 2005-02-28
BR9703624A (pt) 1998-09-01
HUP9701068A3 (en) 2000-07-28
US5977099A (en) 1999-11-02
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
KR100481254B1 (ko) 2005-09-12
JP2009137970A (ja) 2009-06-25
TR199700522A2 (tr) 1998-01-21
AU2612997A (en) 1998-01-08
ID17051A (id) 1997-12-04
CA2208199C (en) 2006-10-24
PT813873E (pt) 2002-06-28
MX9704579A (es) 1998-07-31
AU727851B2 (en) 2001-01-04
ES2172744T3 (es) 2002-10-01
NO972816D0 (no) 1997-06-18
NO972816L (no) 1997-12-22
CA2208199A1 (en) 1997-12-19
HK1006081A1 (en) 1999-02-12
AR007609A1 (es) 1999-11-10
CZ290691B6 (cs) 2002-09-11
NZ328113A (en) 1999-09-29
DE69710390D1 (de) 2002-03-21
KR980000447A (ko) 1998-03-30
PL320628A1 (en) 1997-12-22
HU9701068D0 (en) 1997-08-28
NO313177B1 (no) 2002-08-26
ATE213159T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
TR199700522A3 (tr) Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim.
HUP0202708A3 (en) Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
PT1105123E (pt) Composicoes farmaceuticas contendo inibidores da lipase e quitosano
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
DZ2964A1 (fr) Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
DK1117645T3 (da) Arylsubstituerede propanolaminderivater, fremgangsmåder til fremstilling deraf, lægemidler indeholdende disse forbindelser og anvendelse deraf
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
HUP0104987A3 (en) Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
DK0911385T3 (da) Stanolholdige sammensætninger
NO20031619D0 (no) Substituerte indoler, farmasöytiske blandinger inneholdende slike indoler og deres anvendelse som PPAR-gamma-bindende midler
HUP0103506A3 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors and pharmaceutical composition containing them
NO20011950L (no) Farmasöytiske blandinger som inneholder poly(ADP-ribose) glukohydrolaseinhibitorer og fremgangsmåter for anvendelse avsamme
HK1053787A1 (zh) 含有hiv蛋白酶抑制劑的藥物組合物
TR200100054T2 (tr) Paroksetin metansülfonat
DK1112266T3 (da) Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
NO20024201D0 (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase
HUP0203054A3 (en) Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use
EE05271B1 (et) 7-asaindoolid, meetod nende snteesimiseks, nende kasutamine TNFa v?i fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid
IS4809A (is) Taxóíð, efnasmíði þeirra og lyfjasamsetning sem inniheldur þau
BR9709406B1 (pt) fluorenonas alquiloxiamino substituìdas e composição farmacêutica contendo as mesmas.
TR199501644A2 (tr) Skualen sintetaz inhibitörleri.
ATE297187T1 (de) Resorcinenthaltende zusammensetzung